Off-label prescribing of antidepressants.

BMJ

Population Health Sciences Division, University of Dundee Medical School, Dundee DD2 4BF, UK.

Published: February 2017

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmj.j849DOI Listing

Publication Analysis

Top Keywords

off-label prescribing
4
prescribing antidepressants
4
off-label
1
antidepressants
1

Similar Publications

Quantification of ivermectin in veterinary products consumed off-label as a treatment for COVID-19.

Pharmazie

December 2024

Centre of Excellence for Pharmaceutical Sciences (Pharmacen™), North-West University, Potchefstroom, Republic of South Africa.

The COVID-19 pandemic caused global pandemonium, and due to an unprecedented global response, the popularity and use of (veterinary) ivermectin, amongst many other conceivable 'treatments', experienced a meteoric rise. Ivermectin is a macrocyclic lactone compound belonging to the avermectin drug class and is a registered medicine in many countries, although the most common use is as veterinary medicine. In this study, a fast HPLC method was developed and validated for the quantification of ivermectin in veterinary products that were used off-label by a substantial number of people during COVID-19.

View Article and Find Full Text PDF

Background: A significant number of patients with atrial fibrillation (AF) on direct oral anticoagulants (DOACs) receives off-label or inappropriate doses. This study examines the prevalence, dosages, and clinical outcomes in AF-patients on DOAC therapy admitted to an emergency department (ED).

Methods: This retrospective single-center observational study utilized data from the Heidelberg Registry of Atrial Fibrillation (HERA-FIB), consecutively including patients with AF presenting to the ED of the University Hospital of Heidelberg from June 2009 to March 2020.

View Article and Find Full Text PDF

Background: Dengue fever (DF) is endemic in Pakistan, posing health risks. Recent flooding in 2022 and strong monsoon rains in 2024 have increased the possibility of an epidemic. It is an infectious disease having potentially severe outcomes including thrombocytopenia.

View Article and Find Full Text PDF

Introduction: Benralizumab is an interleukin 5-receptor-blocking drug registered for the treatment of eosinophilic asthma. It has proven efficient and safe in a small phase-II trial in hypereosinophilic syndrome and is currently being investigated in a larger, randomized phase-III trial. We report on real-world experience with benralizumab in 15 patients with severe Hypereosinophilic syndrome (HES) that were refractory to other treatments or on unacceptable steroid doses.

View Article and Find Full Text PDF

A 65-year-old patient presented with recurrent, locally advanced poorly differentiated thyroid cancer despite 2 neck surgeries, and with newly diagnosed brain and skull base metastases. He was treated with palliative stereotactic radiosurgery to the brain and skull base lesions. Thereafter, as no targetable genetic alteration was identified and antiangiogenic multikinase inhibitors were deemed at high risk of hemorrhagic complications, off-label systemic therapies were considered.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!